Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Cash Flow (2023 - 2025)

Kura Oncology (KURA) has disclosed Net Cash Flow for 3 consecutive years, with $53.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 69.25% to $53.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$75.4 million, a 140.27% decrease, with the full-year FY2025 number at -$75.4 million, down 140.27% from a year prior.
  • Net Cash Flow was $53.8 million for Q4 2025 at Kura Oncology, up from $13.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $175.0 million in Q4 2024 to a low of -$173.2 million in Q1 2025.
  • A 3-year average of $274083.3 and a median of $4.2 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1939.89% in 2024, then tumbled 4235.46% in 2025.
  • Kura Oncology's Net Cash Flow stood at $8.6 million in 2023, then surged by 1939.89% to $175.0 million in 2024, then plummeted by 69.25% to $53.8 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Net Cash Flow are $53.8 million (Q4 2025), $13.3 million (Q3 2025), and $30.7 million (Q2 2025).